Biofrontera Inc.(BFRI)Earnings, Financials & Key Ratios
BFRI•NASDAQ
$1.14
$13M mkt cap·Price updated May 6, 2026
AboutBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Show more
- Revenue$42M+11.8%
- EBITDA-$11M+29.3%
- Net Income-$11M+40.7%
- EPS (Diluted)0.00+100.0%
- Gross Margin75.76%+51.2%
- EBITDA Margin-27.21%+36.8%
- Operating Margin-27.21%+41.0%
- Net Margin-25.26%+46.9%
- ROE-141.3%+63.3%
- ROIC-124.26%+40.8%
- Debt/Equity0.59-47.1%
BFRI Key Insights
Biofrontera Inc. (BFRI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 17.2%
- ✓Share count reduced 100.0% through buybacks
- ✓Trading near 52-week high
- ✓Efficient asset utilization: 1.5x turnover
✗Weaknesses
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BFRI Price & Volume
Biofrontera Inc. (BFRI) stock price & volume — 10-year historical chart
Loading chart...
BFRI Growth Metrics
Biofrontera Inc. (BFRI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years17.21%
3 Years13.3%
TTM11.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM40.67%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.44%
Return on Capital
10 Years-92.91%
5 Years-102.06%
3 Years-123.82%
Last Year-84.85%
BFRI Peer Comparison
Biofrontera Inc. (BFRI) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DERM | 106.45M | 5.21 | -7.24 | -29.11% | -15.49% | -45.4% | 1.28 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 GDRX | 880.73M | 2.57 | 30.13 | 0.57% | 3.74% | 4.75% | 0.10 | |
 SKIN | 120.86M | 0.93 | -5.83 | -10.02% | -3.16% | -15.42% | 6.20 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 MCK | 91.09B | 743.67 | 28.91 | 16.22% | 1.09% | |||
 CAH | 45.06B | 191.49 | 29.69 | -1.87% | 0.62% |
Compare BFRI vs Peers
Biofrontera Inc. (BFRI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BFRI Income Statement
Biofrontera Inc. (BFRI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 26.18M | 18.85M | 24.1M | 28.67M | 34.07M | 37.3M | 41.7M |
| Revenue Growth % | - | -28.01% | 27.86% | 18.98% | 18.82% | 9.49% | 11.8% |
| Cost of Goods Sold | 12.41M | 9.07M | 12.74M | 15.19M | 17.44M | 18.61M | 10.11M |
| COGS % of Revenue | 47.39% | 48.1% | 52.87% | 52.96% | 51.2% | 49.88% | 24.24% |
| Gross Profit | 13.77M▲ 0% | 9.78M▼ 29.0% | 11.36M▲ 16.1% | 13.49M▲ 18.8% | 16.63M▲ 23.3% | 18.7M▲ 12.4% | 31.59M▲ 69.0% |
| Gross Margin % | 52.61% | 51.9% | 47.13% | 47.04% | 48.8% | 50.12% | 75.76% |
| Gross Profit Growth % | - | -28.97% | 16.1% | 18.76% | 23.26% | 12.44% | 68.99% |
| Operating Expenses | 28.7M | 19.39M | 36.56M | 32.07M | 39.3M | 35.92M | 42.94M |
| OpEx % of Revenue | 109.6% | 102.86% | 151.7% | 111.84% | 115.36% | 96.3% | 102.97% |
| Selling, General & Admin | 28.7M | 18.12M | 37.21M | 35.87M | 39.13M | 33.84M | 37.75M |
| SG&A % of Revenue | 109.6% | 96.12% | 154.39% | 125.1% | 114.84% | 90.7% | 90.52% |
| Research & Development | 0 | 0 | 0 | 0 | 77K | 2.09M | 3.72M |
| R&D % of Revenue | - | - | - | - | 0.23% | 5.6% | 8.92% |
| Other Operating Expenses | 0 | 1.27M | -650K | -3.8M | 100K | 0 | 1.47M |
| Operating Income | -14.92M▲ 0% | -9.61M▲ 35.6% | -25.2M▼ 162.3% | -18.58M▲ 26.3% | -22.68M▼ 22.0% | -17.21M▲ 24.1% | -11.35M▲ 34.1% |
| Operating Margin % | -57% | -50.96% | -104.57% | -64.8% | -66.56% | -46.14% | -27.21% |
| Operating Income Growth % | - | 35.63% | -162.35% | 26.27% | -22.04% | 24.11% | 34.06% |
| EBITDA | -14.26M | -9.04M | -24.66M | -17.41M | -21.61M | -16.06M | -11.35M |
| EBITDA Margin % | -54.45% | -47.98% | -102.33% | -60.71% | -63.44% | -43.06% | -27.21% |
| EBITDA Growth % | - | 36.56% | -172.68% | 29.41% | -24.15% | 25.69% | 29.34% |
| D&A (Non-Cash Add-back) | 667K | 562K | 540K | 1.17M | 1.06M | 1.15M | 0 |
| EBIT | -8.79M | -8.03M | -37.3M | -238K | -19.52M | -15.63M | 0 |
| Net Interest Income | -2.13M | -2.87M | -344K | -195K | -468K | -2.08M | 0 |
| Interest Income | 25K | 28K | 16K | 175K | 132K | 30K | 0 |
| Interest Expense | 2.16M | 2.9M | 360K | 370K | 600K | 2.11M | -452K |
| Other Income/Expense | 3.97M | -1.32M | -12.46M | 17.97M | 2.56M | -527K | 837K |
| Pretax Income | -10.95M▲ 0% | -10.92M▲ 0.2% | -37.66M▼ 244.7% | -608K▲ 98.4% | -20.12M▼ 3208.7% | -17.74M▲ 11.8% | -10.51M▲ 40.7% |
| Pretax Margin % | -41.82% | -57.95% | -156.25% | -2.12% | -59.04% | -47.55% | -25.2% |
| Income Tax | 33K | 64K | 56K | 32K | 14K | 22K | 25K |
| Effective Tax Rate % | -0.3% | -0.59% | -0.15% | -5.26% | -0.07% | -0.12% | -0.24% |
| Net Income | -10.98M▲ 0% | -10.99M▼ 0.0% | -37.71M▼ 243.3% | -640K▲ 98.3% | -20.13M▼ 3045.5% | -17.76M▲ 11.8% | -10.54M▲ 40.7% |
| Net Margin % | -41.95% | -58.29% | -156.49% | -2.23% | -59.09% | -47.61% | -25.26% |
| Net Income Growth % | - | -0.05% | -243.25% | 98.3% | -3045.47% | 11.78% | 40.67% |
| Net Income (Continuing) | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M | 0 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -18.09▲ 0% | -18.94▼ 4.7% | -44.10▼ 132.8% | -0.61▲ 98.6% | -13.02▼ 2034.4% | -3.22▲ 75.3% | 0.00▲ 100.0% |
| EPS Growth % | - | -4.7% | -132.84% | 98.62% | -2034.43% | 75.27% | 100% |
| EPS (Basic) | -18.09 | -18.94 | -44.10 | -0.61 | -13.02 | -3.22 | 0.00 |
| Diluted Shares Outstanding | 607K | 580K | 855.24K | 1.06M | 1.55M | 5.52M | 0 |
| Basic Shares Outstanding | 607K | 580K | 855.24K | 1.06M | 1.55M | 5.52M | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
BFRI Balance Sheet
Biofrontera Inc. (BFRI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 23.47M | 19.58M | 46.42M | 43.14M | 23.07M | 20.7M | 18.08M |
| Cash & Short-Term Investments | 7.3M | 8.08M | 24.55M | 27.76M | 1.42M | 5.91M | 6.39M |
| Cash Only | 7.3M | 8.08M | 24.55M | 17.21M | 1.34M | 5.91M | 6.39M |
| Short-Term Investments | 0 | 0 | 0 | 10.55M | 78K | 7K | 0 |
| Accounts Receivable | 4.79M | 3.29M | 3.78M | 7.41M | 5.16M | 5.32M | 7.29M |
| Days Sales Outstanding | 66.72 | 63.69 | 57.31 | 94.27 | 55.3 | 52.01 | 63.81 |
| Inventory | 10.48M | 7.09M | 4.46M | 7.17M | 10.91M | 6.65M | 1.43M |
| Days Inventory Outstanding | 308.29 | 285.49 | 127.7 | 172.3 | 228.24 | 130.37 | 51.48 |
| Other Current Assets | 186K | 619K | 12.81M | 286K | 5.28M | 2.83M | 2.97M |
| Total Non-Current Assets | 5.28M | 4.56M | 6.8M | 7.74M | 4.86M | 1.4M | 10.48M |
| Property, Plant & Equipment | 503K | 370K | 267K | 1.58M | 1.75M | 983K | 3.74M |
| Fixed Asset Turnover | 52.05x | 50.94x | 90.26x | 18.16x | 19.51x | 37.95x | 11.15x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4.29M | 3.87M | 3.45M | 3.03M | 2.63M | 35K | 2.65M |
| Long-Term Investments | 0 | 0 | 2.81M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 494K | 323K | 3.08M | 3.13M | 482K | 383K | 4.09M |
| Total Assets | 28.75M▲ 0% | 24.14M▼ 16.0% | 53.22M▲ 120.5% | 50.88M▼ 4.4% | 27.93M▼ 45.1% | 22.1M▼ 20.9% | 28.56M▲ 29.2% |
| Asset Turnover | 0.91x | 0.78x | 0.45x | 0.56x | 1.22x | 1.69x | 1.46x |
| Asset Growth % | - | -16.05% | 120.48% | -4.39% | -45.11% | -20.88% | 29.24% |
| Total Current Liabilities | 11.74M | 4.42M | 13.84M | 20.89M | 18.09M | 12.02M | 11.89M |
| Accounts Payable | 7.81M | 1.51M | 658K | 1.28M | 8.91M | 1.86M | 1.85M |
| Days Payables Outstanding | 229.86 | 60.95 | 18.85 | 30.72 | 186.35 | 36.41 | 66.96 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 3.9M | 0 | 332K |
| Deferred Revenue (Current) | 0 | 0 | 3.24M | 6.94M | 0 | 0 | 0 |
| Other Current Liabilities | 1.88M | 569K | 6.7M | 3.3M | 3.02M | 1.05M | 11.56M |
| Current Ratio | 2.00x | 4.43x | 3.36x | 2.06x | 1.28x | 1.72x | 1.52x |
| Quick Ratio | 1.11x | 2.82x | 3.03x | 1.72x | 0.67x | 1.17x | 1.40x |
| Cash Conversion Cycle | 145.15 | 288.22 | 166.16 | 235.85 | 97.19 | 145.97 | 48.32 |
| Total Non-Current Liabilities | 47.19M | 13.89M | 28.05M | 6.11M | 5.05M | 5.65M | 6.19M |
| Long-Term Debt | 38.2M | 0 | 0 | 0 | 0 | 4.1M | 5.83M |
| Capital Lease Obligations | 0 | 0 | 0 | 848K | 804K | 276K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 58K | 62K | 18.5M | 2.86M | 4.25M | 1.27M | 360K |
| Total Liabilities | 58.93M | 18.31M | 41.88M | 27.01M | 23.14M | 17.67M | 18.08M |
| Total Debt | 38.2M | 0 | 0 | 1.35M | 5.4M | 4.92M | 6.16M |
| Net Debt | 30.9M | -8.08M | -24.55M | -15.86M | 4.06M | -983K | -231K |
| Debt / Equity | - | - | - | 0.06x | 1.13x | 1.11x | 0.59x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -6.91x | -3.32x | -70.00x | -50.22x | -37.80x | -8.17x | - |
| Total Equity | -30.18M▲ 0% | 5.83M▲ 119.3% | 11.34M▲ 94.5% | 23.88M▲ 110.6% | 4.79M▼ 79.9% | 4.43M▼ 7.5% | 10.48M▲ 136.4% |
| Equity Growth % | - | 119.31% | 94.54% | 110.6% | -79.93% | -7.51% | 136.41% |
| Book Value per Share | -49.72 | 10.05 | 13.26 | 22.59 | 3.10 | 0.80 | - |
| Total Shareholders' Equity | -30.18M | 5.83M | 11.34M | 23.88M | 4.79M | 4.43M | 10.48M |
| Common Stock | 0 | 8K | 17K | 1K | 2K | 9K | 12K |
| Retained Earnings | -30.18M | -41.17M | -78.88M | -79.52M | -99.65M | -117.41M | -127.94M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BFRI Cash Flow Statement
Biofrontera Inc. (BFRI) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -37.68M | -12.37M | -26.71M | -16.2M | -24.89M | -10.27M | -13.36M |
| Operating CF Margin % | -143.91% | -65.62% | -110.85% | -56.49% | -73.07% | -27.53% | -32.04% |
| Operating CF Growth % | - | 67.17% | -115.98% | 39.36% | -53.68% | 58.75% | -30.1% |
| Net Income | -10.98M | -10.99M | -37.71M | -640K | -20.13M | -17.76M | -10.54M |
| Depreciation & Amortization | 667K | 562K | 540K | 1.17M | 1.06M | 1.15M | 138K |
| Stock-Based Compensation | 0 | 0 | 129K | 1.85M | 1.04M | 1.02M | 951K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.42M | 883K | 11.83M | -21.37M | -2.48M | -891K | -3.91M |
| Working Capital Changes | -23.94M | -2.83M | -1.5M | 2.79M | -4.39M | 6.21M | 0 |
| Change in Receivables | -757K | 1.17M | -12M | 4.92M | 4.93M | -313K | -1.91M |
| Change in Inventory | -3.54M | -273K | 2.59M | -2.81M | -3.75M | 4.23M | 1.45M |
| Change in Payables | 1.44M | -3.4M | -773K | 0 | 6.42M | -1.81M | -2K |
| Cash from Investing | 25.39M | 0 | -11K | -5.16M | 619K | -3K | 3M |
| Capital Expenditures | -538K | 0 | -11K | -38K | -5K | -10K | -2K |
| CapEx % of Revenue | 2.05% | - | 0.05% | 0.13% | 0.01% | 0.03% | 0% |
| Acquisitions | 25.93M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -50K | 3M |
| Cash from Financing | 16.4M | 13.19M | 43.19M | 14.02M | 8.41M | 14.84M | 10.85M |
| Debt Issued (Net) | 13.5M | 8.79M | 0 | 0 | 3.9M | -265K | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.9M | 4.4M | 13.25M | 4.63M | 0 | 7.44M | 10.85M |
| Net Change in Cash | 4.12M▲ 0% | 825K▼ 80.0% | 16.46M▲ 1895.8% | -7.33M▼ 144.5% | -15.87M▼ 116.3% | 4.56M▲ 128.8% | 487K▼ 89.3% |
| Free Cash Flow | -38.22M▲ 0% | -12.37M▲ 67.6% | -26.73M▼ 116.1% | -16.24M▲ 39.2% | -24.9M▼ 53.4% | -10.33M▲ 58.5% | -13.36M▼ 29.4% |
| FCF Margin % | -145.96% | -65.62% | -110.9% | -56.63% | -73.08% | -27.69% | -32.04% |
| FCF Growth % | - | 67.63% | -116.07% | 39.25% | -53.35% | 58.51% | -29.36% |
| FCF per Share | -62.96 | -21.33 | -31.25 | -15.36 | -16.10 | -1.87 | - |
| FCF Conversion (FCF/Net Income) | 3.43x | 1.13x | 0.71x | 25.31x | 1.24x | 0.58x | 1.27x |
| Interest Paid | 1.71M | 3.07M | 2K | 1K | 147K | 1.73M | 0 |
| Taxes Paid | 50K | 64K | 56K | 32K | 15K | 24K | 0 |
BFRI Key Ratios
Biofrontera Inc. (BFRI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -188.52% | -439.39% | -3.63% | -140.43% | -384.98% | -141.3% |
| Return on Invested Capital (ROIC) | -1556.54% | - | - | -173.85% | -201.69% | -209.9% | -124.26% |
| Gross Margin | 52.61% | 51.9% | 47.13% | 47.04% | 48.8% | 50.12% | 75.76% |
| Net Margin | -41.95% | -58.29% | -156.49% | -2.23% | -59.09% | -47.61% | -25.26% |
| Debt / Equity | - | - | - | 0.06x | 1.13x | 1.11x | 0.59x |
| Interest Coverage | -6.91x | -3.32x | -70.00x | -50.22x | -37.80x | -8.17x | - |
| FCF Conversion | 3.43x | 1.13x | 0.71x | 25.31x | 1.24x | 0.58x | 1.27x |
| Revenue Growth | - | -28.01% | 27.86% | 18.98% | 18.82% | 9.49% | 11.8% |
BFRI Frequently Asked Questions
Biofrontera Inc. (BFRI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Biofrontera Inc. (BFRI) reported $41.7M in revenue for fiscal year 2025. This represents a 59% increase from $26.2M in 2019.
Biofrontera Inc. (BFRI) grew revenue by 11.8% over the past year. This is steady growth.
Biofrontera Inc. (BFRI) reported a net loss of $10.5M for fiscal year 2025.
Dividend & Returns
Biofrontera Inc. (BFRI) has a return on equity (ROE) of -141.3%. Negative ROE indicates the company is unprofitable.
Biofrontera Inc. (BFRI) had negative free cash flow of $13.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More BFRI
Biofrontera Inc. (BFRI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates